Influence of combined oral contraceptives on the periodontal condition by Domingues, Roberta Santos et al.
  Universidade de São Paulo
 
2013-08-02
 
Influence of combined oral contraceptives on
the periodontal condition
 
 
JOURNAL OF APPLIED ORAL SCIENCE, BAURU-SP, v. 20, n. 2, supl. 1, Part 2, pp. 253-259, MAR-
APR, 2012
http://www.producao.usp.br/handle/BDPI/36741
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Sem comunidade WoS
J Appl Oral Sci. 253
ABSTRACT
www.scielo.br/jaos
	
				
periodontal condition
Roberta Santos DOMINGUES1, Bruna Fidêncio Rahal FERRAZ1, Sebastião Luiz Aguiar GREGHI2, Maria Lúcia Rubo 
de REZENDE2, Euloir PASSANEZI3, Adriana Campos Passanezi SANT’ANA2
1- DDS, MS, Division of Periodontology, Department of Prosthodontics, Bauru School of Dentistry, University of São Paulo, Bauru, SP, Brazil.
2- DDS, PhD, Associate Professor, Division of Periodontology, Department of Prosthodontics, Bauru School of Dentistry, University of São Paulo, Bauru, SP, Brazil.
3- DDS, PhD, Professor and Chair, Division of Periodontology, Department of Prosthodontics, Bauru School of Dentistry, University of São Paulo, Bauru, SP, Brazil.
Corresponding address: Adriana Campos Passanezi Sant’Ana - Disciplina de Periodontia - Departamento de Prótese - Faculdade de Odontologia de Bauru 
– Universidade de São Paulo (FOB/USP) - Al. Octávio Pinheiro Brisolla, 9-75 - - 17012-901 - Bauru - SP - Brazil - Phone +55 (14) 3235-8366 - Fax + (14) 
3235-8245 - e-mail: drisantana@yahoo.com.br
	
												
Most studies investigating the impact of oral contraceptives have been performed some years ago, when the level of sexual hormones was greater than the actual formulations. 
Objective: The aim of this study was to evaluate the effects of current combined oral 
contraceptives (COC) on periodontal tissues, correlating the clinical parameters examined 
with the total duration of continuous oral contraceptive intake. Material and methods: 
	!	"#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year were included in the test group. The control group was composed by 25 patients at 
the same age range reporting no use of hormone-based contraceptive methods. Clinical 
parameters investigated included pocket probing depth (PD), clinical attachment level (CAL), 
sulcular bleeding index (SBI) and plaque index (Pl.I). Data were statistically evaluated 
by unpaired t test, Pearson’s correlation test and Spearman’s correlation test. Results: 
The test group showed increased PD (2.228±0.011 x 2.154±0.012; p<0.0001) and SBI 
%&''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groups were found in CAL (0.435±0.01 x 0.412±0.01; p=0.11). The control group showed 
greater Pl.I than the test group (0.206±0.007 x 0.303±0.008; p<0.0001). No correlation 
between the duration of oral contraceptive intake, age and periodontal parameters was 
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of the level of plaque accumulation or total duration of medication intake, resulting in 
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INTRODUCTION
Gingivitis associated with hormonal changes, 
such as those observed in puberty and pregnancy, 
seems to be dependent on, but unrelated to, 
the amount of plaque accumulation3. The main 
premenopausal steroid sex hormones (estradiol 
and progesterone) are responsible not only for the 
physiological changes in women at different phases 
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
7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actions that can affect different organ systems 
including the oral cavity15,21.
Clinically, a positive correlation between 
estradiol and progesterone serum levels and 
gingival inflammation, regardless the amount 
of plaque accumulation, has been described in 
puberty-associated gingivitis15,17. It has also been 
suggested that the exacerbated inflammatory 
response to irritant factors could be explained 
by qualitative changes in microbiota2,11,17,21 or 
host response to plaque accumulation2,4,9,10,14,21. 
Some bacterial species possess the ability to 
use menadione as a substitute for vitamin K, 
leading to an explosion of its levels at subgingival 
environment, resulting in the clinical presentation 
	
 $$ 	2,11,17,21. Also, increased 
sex hormone levels in serum could induce tissue 
destruction by activating matrix metalloproteinases 
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proteins (MMPs)12.
The use of hormonal contraceptives by women 
at their reproductive life has been considered to 
		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	2,5,15,16,21. 
Clinical studies reported higher prevalence of 
gingival inflammation, loss of attachment and 
gingival enlargement in woman taking hormone-
based oral contraceptives8,10,19,21. However, recent 
studies based on large23 or small20 population 
samples suggested that current combined oral 
contraceptives (COC) do not affect periodontal 
health, possibly related to their lower concentration 
of progesterone and estradiol than previously used 
medications16&V$		
associated to high concentrations of sex hormones 
present in COC19. It is also noteworthy that an 
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the time of use of COC10,19.
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of oral contraceptives on periodontal tissues were 
published during the 1960’s and 1970’s, when 
hormonal doses of contraceptives were higher than 
those of current formulations, the aim of this study 
was to investigate the effects of current low-dose 
COC on clinical periodontal conditions of healthy 
young adult women continuously taking such 
medications for at least 1 year.
MATERIAL AND METHODS
Sample selection
Ethical approval was obtained from the 
Bauru School of Dentistry Ethical Board prior to 
commencement and written informed consent 
was obtained from all subjects prior to enrollment. 
Were invited to participate in this study 50 
women aged 19-35 years old, systemically health, 
presenting at least 24 teeth (except for third 
molars). To be included in the test group (n=25) 
women should report continuous use of COC 
(progesterone+estradiol) for at least 1 year. Women 
included in the control group (n=25) should report 
no use of COC.
Exclusion criteria were: current pregnancy or 
delivery within 12 months prior to data collection; 
smoking or former smokers; drugs or alcohol 
abuse; mouth breathing; history of radiotherapy 
or chemotherapy in the past 5 years; early or 
premature menopause; breastfeeding; presence 
	
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response to plaque accumulation (e.g.: diabetes 
mellitus); use of antibiotics, non-steroidal or 
	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6 months; periodontal treatment, including 
professional prophylaxis, within the 6-month 
period prior to data collection; use of drugs that 
could induce gingival enlargement (e.g.: calcium 
channel blockers, cyclosporine or anti-convulsants); 
interrupted use of COC; and hormone replacement 
therapy.
Volunteers were selected among dental 
undergraduate and graduate students at Bauru 
School of Dentistry, University of São Paulo, Brazil, 
between August and November 2008. For each 
patient included in the test group, a volunteer at the 
same or similar age not reporting the use of COC 
and not presenting any of the exclusion criteria was 
selected to compose the control group, in such a 
way that the test and control groups were composed 
by 25 age-matched women each.
A detailed questionnaire was completed by all 
patients included in the study, recording full medical 
history and COC intake before clinical examination. 
Test group volunteers were questioned about the 
name, dose and total uninterrupted use of combined 
oral contraceptives, which were recorded in patient 
	&
Periodontal examination
Patients were evaluated by a previously 
calibrated (K=0.92 for probing depth and K=0.89 
for clinical attachment level), single blinded 
examiner according to pocket probing depth (PD), 
gingival recession (REC) or hyperplasia (HP), clinical 
attachment level (CAL), sulcular bleeding index 
(SBI) and plaque index (Pl.I). All patients were 
examined using good illumination and standardized 
conditions. Full-mouth examination was performed 
at six sites per tooth for PD, REC, HP, CAL and SBI 
and at four sites per tooth for Pl.I, except for third 
molars.
PD - measured with a 15-mm conventional 
periodontal probe (Hu-Friedy, Chicago, IL, USA), 
determined by the distance from gingival margin to 
the bottom of the gingival sulcus or pocket;
REC and HP - measured with a 15-mm 
conventional periodontal probe (Hu-Friedy) as the 
distance from gingival margin to cementoenamel 
]	F^_"&`^F	
record as a negative value and HP was recorded as 
a positive value, in order to allow the determination 
of CAL;
F{|
	F^_	
bottom of the sulcus or pocket, derived from the 
	
}~`^F	}7/
the formula27:
CAL=PD-[REC or HP]CAL=PD-[REC or HP]
Pl.I - The presence or absence of plaque was 
determined following the proposal of O’Leary, Drake 
and Naylor18 (1972). According to that, the presence 
of plaque was recorded as 1 and its absence as 0;
SBI - the occurrence of bleeding on gentle 
probing was observed within 15 s after removal of 
the probe from the sulcus and recorded as present 
(1) or absent (0), as proposed by Ainamo & Bay1 
(1975).
!"	#		$	%		&	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Statistical analysis 
Data were analyzed using the GraphPad Prism 
5 statistical software (GraphPad Software Inc., San 
Diego, CA, USA). Determination of sample size was 
based on other studies reporting the investigation 
	
 FF  	 		 16,20. For 
statistical purposes, the unit of analysis was 
the site. The comparison of clinical periodontal 
parameters (PD, CAL, SBI and Pl.I) between test 
and control groups was performed by unpaired t 
   $  	
!=0.05). The 
correlation between the total duration of COC 
intake, age and clinical periodontal parameters was 
investigated by Pearson’s correlation test for linear 
measurements (PD and CAL) and by Spearman’s 
correlation test for non-linear measurements (SBI 
}&"$	
!&
RESULTS
The mean age for test and control groups did 
	
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t test). The mean duration 
of COC intake for the test group was 4.34±2.49 
years. Among the various COC formulations used by 
the subjects, estrogen content ranged from 0.015 
to 0.04 mg and progestin content ranged from 
0.075 to 3.0 mg (Figure 1). The mean duration of 
COC intake in the test group was 4.44±2.42 years.
Clinical periodontal parameters of patients 
included in test and control groups are shown at 
Table 1. Full-mouth evaluation provided the analysis 
of 4,116 sites for PD, CAL and SBI and 2,735 sites 
for Pl.I at control group, and 4,134 sites for PD, 
CAL and SBI and 2,757 sites for Pl.I for the test 
group. Comparative analysis by unpaired t test 
showed that test group patients presented greater 
}~W		9%&%%%"&=	$
differences in CAL were found between groups 
(p=0.11). Controls showed increased Pl.I than test 
group (p<0.0001).
The analysis by Pearson’s and Spearman’s 
correlation test in the test group (Table 2) showed 
	$		
total duration of COC intake or age and clinical 
		  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
Brand # Progestin and estradiol concentration Number of patients 
1 3 mg drospirenone; 0.02 mg ethynil estradiol 5
2 0.60 mg gestoden; 0.015 mg ethynil estradiol 1
3 3 mg drospirenone; 0.03 mg ethynil estradiol 4
4 0.075 mg gestoden; 0.03 mg ethynil estradiol 1
5 2 mg cyproterone; 0.035 mg ethynil estradiol 2
6 0.075 mg gestoden; 0.2 mg ethynil estradiol 1
7 7 pills of 0.25 mg desogestrol and 0.04 mg ethynil estradiol; 14 pills of 0.125 mg 
desogestrol and 0.03 mg ethynil estradiol
5
8 2 mg cyproterone; 0.035 mg ethynil estradiol 2
9 2 mg acetate clormadiome; 0.03 mg ethynil estradiol 1
10 0.075 mg gestoden; 0.02 mg ethynil estradiol 2
11 0.15mg desogestrol; 0.02 mg ethynil estradiol
Figure 1- Concentration of sex hormones (progestin and estradiol) of the different brands of combined oral contraceptives 
consumed by patients in the test group
Test Control P value
n Mean SD n Mean SD
PD 4134 2.228 0.011 4116 2.154 0.012 
CAL 4134 0.435 0.010 4116 0.412 0.010 p=0.1184
SBI 4134 0.229 0.006 4116 0.148 0.005 
PI.I 2757 0.206 0.007 2735 0.303 0.008 
Table 1- Clinical periodontal parameters in the test and control groups (unpaired t test)
PD– probing depth (in millimeters); CAL– clinical attachment level (in millimeters); SBI– sulcus bleeding index (0- absence; 
1- presence); Pl.I– plaque index (0- absence; 1- presence); n=number of sites evaluated; SD- standard deviation; 
	
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positive correlation was observed between CAL and 
PD, SBI and Pl.I and CAL and SBI (p<0.05).
The analysis by Pearson’s and Spearman’s 
correlation tests in the control group (Table 3) 
showed a positive correlation between age and 
CAL, PD and Pl.I, CAL and SBI, and CAL and Pl.I.
DISCUSSION
$	

low-dose COC on clinical periodontal parameters 
of systemically healthy non-smoking women, and 
the correlation among these parameters, duration 
of usage and age. Our findings suggest that 
current COC therapy results in greater PD and SBI, 
regardless of the amount of plaque accumulation 
or duration of contraceptive intake.
Recently, Haerian-Ardakaniet, et al.6 (2010) 
	
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pills on periodontal health in young women, aged 
17 to 35 years, as evaluated in our study. Patients 
have completed a questionnaire to assess current 
and previous oral contraceptive use. Periodontal 
examination included Pl.I, SBI, PD and CAL at six 
sites per tooth, as also performed in the present 
study. A total of 35 women taking oral contraceptives 
for at least 2 years were compared with 35 women 
not taking the medication, matched by age range 
and socioeconomic, occupational and educational 
levels. The results obtained showed that, although 
no difference in Pl.I was observed, patients taking 
	$$$	
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were found between groups with respect to PD and 
F{|& W 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by Kalkwarf, et al.7 (1978), who suggested that 
women taking oral contraceptives had more gingival 
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Duration of   use* PD* CAL* SBI** PI.I**
Age r=0.471 r=-0.252 r=-0.366 r=-0.200 ---
p=0.018† p=0.225 p=0.071 p=0.338
Duration of use --- r=-0.133 r=-0.095 r=0.039 ---
p=0.652 p=0.652 p=0.673
PD r=-0.133 --- r=0.392 r=-0.005 r=0.005
p=0.527  p=0.747 p=0.800
CAL r=-0.095 r=0.392 --- r=0.057 r=-0.017
p=0.675  p=0.00007† p=0.381
SBI r=0.088 r=-0.001 r=0.067 --- r=-0.060
p=0.527 p=0.930 p=0.000002† p=0.002†
Table 2- Correlation between age, total duration of oral contraceptive therapy and clinical periodontal parameters in test 
group
PD– probing depth (in millimeters); CAL– clinical attachment level (in millimeters); SBI– sulcus bleeding index (0 - 
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PD* CAL* SBI** PI.I**
Age r=0.014 r=0.493 r=0.161 r=0.000
p=0.948 p=0.012† p=0.443 p=1.000 
PD --- r=0.026 r=-0.006 r=0.089
p=0.105 p=0.699 
CAL r=0.026 --- r=0.140 r=0.052
p=0.106  p=0.007†
SBI r=-0.006 r=0.117 --- r=0.008
p=0.724  p=0.669
Table 3- Correlation between age and clinical periodontal parameters in the control group
PD– probing depth (in millimeters); CAL– clinical attachment level (in millimeters); SBI– sulcus bleeding index (0 - 
	!"#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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the medications, as shown in the present study. 
No differences were found among patients taking 
the different medications for 1-11 months, 12-35 
	 	+	7  
	 
medication brands.
The fundamental principles of COC are based 
on the use of hormones to simulate a pregnancy 
state to prevent ovulation to occur. Some previous 
study have reported that physiological hormonal 
imbalances occurring during puberty, pregnancy 
or menstrual cycle are associated with gingival 
inflammation, mainly related to deeper PD 
measures, gingival enlargement and bleeding 
on probing2,12,13,15,19,25. The incidence of gingival 
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to be positively correlated with plasma steroid 
hormone concentration and independent from 
dental plaque scores15.
Our findings showed an greater PD and 
bleeding on probing in women taking COC for 
at least 1 year, which is agreement with other 
reports in literature6,12,15,16,21. Tilakaratne, et al.24 
(2000) investigated 32 women taking hormonal 
contraceptives for less than 2 years, 17 of them 
for 2-4 years and a matched control group of 39 
women not taking the medication. The results 
obtained suggested that women taking pills had 
similar oral hygiene levels than women who did not 
#&	7$$	
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pills for 2-4 years had higher CAL than controls, 
which was not observed in the present study, since 
no differences in CAL was observed between test 
and control groups.
$$$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}~
related to gingival hyperplasia or “false pocketing”, 
rather than to destruction of supporting periodontal 
tissues2,12,16,21, similarly to those observed during 
pregnancy or puberty2,15,21. 	7$
were not observed in other studies9,14,28. It has 
been discussed that, although some qualitative 
alterations occur in the subgingival bacterial 
	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	7 	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do not present alterations on clinical parameters, 
such as gingival index, Pl.I and PD9. However, 
considering the disturbances in microvascular 
structure and functions, vasodilatation, increased 
7      
	 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of progesterone and estrogen, the presence of 
greater PD in the test group could be explained 
by the fact that these alterations exacerbate the 
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hyperplasia13,15,22.
As discussed by Kalkwarf, et al.7 (1978), the 
increased inflammatory response observed in 
patients taking oral contraceptives is probably 
	

	
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	

progesterone, which has been shown to alter the 
microvascular topography and permeability of 
gingival tissues, increase the number of PMN within 
gingival sulcus and, in combination with estradiol, 
increase the synthesis of PGE2 in gingival tissues. 
According to them, each of these mechanisms 
could be responsible for causing an exaggerated 
gingival response to local irritants. As their study 
was conducted in 1978, when the concentrations 
of sex hormones in the medications formulations 
were higher than those existing currently, it 
seemed reasonable that these negative adverse 

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of the present study indicate that the current COC 
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more bleeding on probing and greater PD were 
observed in test than control groups.
Such result might be due to the possible 
absence of receptors to these sex hormones 
on the periodontal tissues, suggesting that any 
pharmacological effects exerted by estrogen and 
progesterone on this tissue are indirect9. Another 
	 /	 
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$ 	 
that current COC present extremely low dosage 
of estrogen and progesterone, not contributing 
$ 	 		  	$	7
especially in women that maintain optimal hygiene 
habits15,18. However, it should be emphasized that 
there are reports of the presence of estrogen and 
progesterone receptors in the periodontal tissues25,26 
making alterations on cytokine and prostaglandin 
production in association with disturbances in the 
microvascular system and higher levels of certain 
bacterial species, as a result of the effects of higher 
serum levels of sex hormones during the use of oral 
contraceptives. These arguments are supportive to 
the belief that women taking this medicine are more 
susceptible to the development and progression of 
periodontal diseases2,10,11,14,16,24.
In the methodological design of the study, 
special care was taken to control other variables 
 	  		
 $$
enlargement or periodontal destruction, including 
smoking habits, diabetes, previous periodontal 
7  	
  	7 	$
	&
	7 	
FF	
fairly investigated in this study. Patients taking 
FF	$		

accumulation than controls, though showing higher 
W$}~&$$
with other reports in literature that suggested that 
 $ 	
 $$ 	  
with physiological or pathological imbalances in sex 
hormones serum levels is not directly correlated to 
the amount of plaque accumulation2,7,9-11,14,21,28. In 
addition, no correlation between Pl.I and PD or CAL 
DOMINGUES RS, FERRAZ BFR, GREGHI SLA, REZENDE MLR, PASSANEZI E, SANT’ANA ACP
2012;20(2):253-9
J Appl Oral Sci. 258
#$$		
SBI were observed in the test group, reinforcing 
these results.
This exacerbated host response could be credited 
to a qualitative change in subgingival microbiota 
     / 		 7
as suggested before11,14,17,19, or to an alteration of 
host response to plaque accumulation2,12,15,21. Some 
studies suggested that the elevation in sex hormone 
levels result in an increased synthesis of cytokines 
and prostaglandins that are intimately associated 
with tissue destruction and bone resorption, by 
activating matrix metalloproteinases and proteolytic 
enzymes as well as by osteoclast formation12.
Brusca, et al.5 (2010), after investigating the 
	
			$$
	 	
 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				$ 
the host’s periodontal status in 92 women aged 
19-40 years, showed that women taking oral 
	 	  $  
the prevalence of severe periodontitis, specially 
smokers. Also, these women had higher numbers 
of cultures positive for Candida sp., which were 
associated with P. gingivalis and P. intermedia.
It is known that not only the prevalence, but 
also the periodontal disease severity increases with 
age due to a prolonged exposure to numerous risk 
factors throughout life. This study did not obtain 
a positive correlation between Pl.I, SBI and PD 
 $7     $
positive correlation between CAL and age in the 
control group. Other authors have reported positive 
correlation between age and PD17,28, and between 
age and loss of attachment21.
The hormonal dosage and the total duration of 
oral contraceptive intake are two possible factors 
$  

 	
   	 
periodontal condition. Considering the increased 
production of pro-inflammatory cytokines and 
prostaglandins resultant from elevated levels of 
these hormones, it seems reasonable to suggest 
that a continued exposure for a long period 
of oral contraceptive use results in a higher 
risk to periodontal disease development and 
progression7,9,10,12,14. In this study, there was no 
$			
the clinical parameters analyzed the total duration 
	
 	 	 #&  $ 
be explained by the low hormonal dosage of the 
current oral contraceptive formulations used by the 
patients selected in this study, in agreement with 
other results obtained with women taking low-dose 
oral contraceptives, which found no statistically 
$

20,23. 
However these results are contradictory as it has 
been observed that women taking COC with low 
hormonal dosage present greater periodontal 
	7$}~		

than women not taking these medications16. In 
addition, Knight and Wade10 (1974) found that 
subjects who had been on oral contraceptive 
therapy for longer than 1.5 years showed increased 
attachment loss than those taking contraceptives 
for a shorter period of time or those who did not 
report oral contraceptive intake.
^	$	
		
on the periodontal condition has been evaluated, 
several mechanisms involved in the process are yet 
to be explained13,19,21,22. Apart from that, there are 
still a small number of studies analyzing the effects 
of current COC, which present a reduced hormonal 
dosage in comparison with the oral contraceptives 
evaluated by most of the studies published on this 
subject. Therefore, the effects of these medications 
in the development and progression of gingival 
			#	&	
to elucidate and complement the results obtained 
here, additional studies must be developed 
examining the effects of current COC intake for 


		
	
on the periodontal tissues.
CONCLUSIONS
In summary, currently available COC might 
influence the periodontal condition of women 
taking these medications for at least 12 months 
continuously, regardless of age and amount of 
plaque accumulation, resulting in increased PD 
and SBI and a slight tendency to develop loss of 
attachment.
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